^
    No biomarker
    GBM
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    TNFA overexpression
    GBM
    bevacizumab
    Resistant
    :
    C3
    Acta Neuropathol Commun - 3wk
    VEGFA overexpression
    GBM
    bevacizumab
    Resistant
    :
    D
    Biomolecules - 3wk
    IDH1 overexpression
    GBM
    bevacizumab
    Resistant
    :
    D
    Biomolecules - 3wk
    No biomarker
    GBM
    Byvasda (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Brain Cancer
    lomustine
    Sensitive
    :
    A1
    No biomarker
    Astrocytoma
    everolimus
    Sensitive
    :
    A1
    No biomarker
    Astrocytoma
    carmustine
    Sensitive
    :
    A1
    No biomarker
    Ependymoma
    carmustine
    Sensitive
    :
    A1
    No biomarker
    Medulloblastoma
    carmustine
    Sensitive
    :
    A1
    No biomarker
    Anaplastic Astrocytoma
    temozolomide
    Sensitive
    :
    A1
    No biomarker
    GBM
    bevacizumab
    Sensitive
    :
    A1
    No biomarker
    Glioma
    carmustine
    Sensitive
    :
    A1
    No biomarker
    GBM
    temozolomide
    Sensitive
    :
    A1
    No biomarker
    GBM
    carmustine
    Sensitive
    :
    A1
    No biomarker
    GBM
    Zirabev (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    GBM
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    GBM
    PCV
    Sensitive
    :
    A2
    No biomarker
    Anaplastic Astrocytoma
    PCV
    Sensitive
    :
    A2
    No biomarker
    Glioma
    PCV
    Sensitive
    :
    A2
    MGMT promoter methylation
    GBM
    temozolomide
    Sensitive
    :
    A2
    No biomarker
    Oligodendroglioma
    temozolomide
    Sensitive
    :
    A2
    No biomarker
    Glioma
    temozolomide
    Sensitive
    :
    A2
    No biomarker
    Meningioma
    bevacizumab + everolimus
    Sensitive
    :
    A2
    No biomarker
    Meningioma
    bevacizumab
    Sensitive
    :
    A2
    No biomarker
    Meningioma
    sunitinib
    Sensitive
    :
    A2
    No biomarker
    Medulloblastoma
    cisplatin + cyclophosphamide oral + vincristine
    Sensitive
    :
    A2
    No biomarker
    Medulloblastoma
    cisplatin + vincristine + lomustine
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES